Vanda Pharmaceuticals Inc. Form 3 April 12, 2006 UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB APPROVAL FORM 3 Washington, D.C. 20549 OMB Number:

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

2. Date of Event Requiring Statement (Month/Day/Year)	^g 3. Issuer Name and Ticker or Trading Symbol Vanda Pharmaceuticals Inc. [VNDA]			
04/12/2006	4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)		
	(Check all applicable)			
	X Officer Other (give title below) (specify below)	 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person 		
	VP of Manufacturing			
Table I - N	Non-Derivative Securities	Beneficially Owned		
	Owned Ownership Ov	Nature of Indirect Beneficial /nership str. 5)		
ach class of securities benefic	ially SEC 1473 (7-02)			
ained in this form are not ond unless the form displ MB control number.	ays a	s, convertible securities)		
	Statement (Month/Day/Year) 04/12/2006 Table I - N 2. Amount o Beneficially (Instr. 4) ach class of securities benefic spond to the collection of ained in this form are not ond unless the form displ MB control number.	(Month/Day/Year) Vanda Pharmaceuticals Ind 04/12/2006 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)		

1. Title of Derivative Security	2. Date Exercisable and		3. Title and Amount of		4.	5.	6. Nature of
(Instr. 4)	Expiration Date		Securities Underlying		Conversion	Ownership	Indirect Beneficial
	(Month/Day/Year)		Derivative Security		or Exercise	Form of	Ownership
			(Instr. 4)		Price of	Derivative	(Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect (I)	

3235-0104

January 31,

2005

0.5

Expires:

response...

Estimated average burden hours per

Edgar Filing: Vanda Pharmaceuticals Inc. - Form 3

						(Instr. 5)	
	08/15/2006(1)				\$ 0.33 <u>(4)</u>	D	Â
Nonqualified Stock Option (Right to Buy)	12/29/2006(2)	12/29/2015	Common Stock	13,100 (3)	\$ 4.73 <u>(4)</u>	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Phadke Deepak Shripad 9605 MEDICAL CENTER DRIVE SUITE 300 ROCKVILLE, MD 20850	Â	Â	VP of Manufacturing	Â		
Signatures						

/s/ Deepak Phadke	04/12/2006		
<u>**</u> Signature of	Date		

Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Exercisable with respect to 25% of the shares on 08/15/06. Exercisable with respect to an additional 2.08333% of the aggregate option share total each month thereafter.
- (2) Exercisable with respect to 25% of the shares on 12/29/06. Exercisable with respect to an additional 2.08333% of the aggregate option share total each month thereafter.
- (3) Reflects a 1-for-3.309755 reverse stock split to occur immediately following the effectiveness of the registration statement covering the issuer's initial public offering.
- (4) Reflects the converted exercise price of each option share pursuant to the 1-for-3.309755 reverse stock split to occur immediately following the effectiveness of the resistration statement covering the issuer's initial public offering.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.